Downloads
Revenue

Description

感谢使用良医汇-罕见病新进展,一键获取罕见病诊疗知识工具。
罕见病是医生实用的知识工具。提供国内外前沿的罕见病学术进展;提供专业系统的学习课程;打造国内罕见病专家团队;解读罕见病国内外热点资讯。
【罕见百科】
收录国内外罕见病诊疗指南,各类罕见病知识持续更新,分享名院名医诊疗经验为临床诊疗提供参考。
【罕见好课】
从诊断、治疗、康复到护理全程全方位的罕见病系统专业课程,助力罕见病规范诊疗。
【罕见药典】
综合国内外罕见病药品信息,竞争锁定对症药物。
【罕见名医】
展示大咖风采,罕见病患者寻医问诊不迷路,快速找到对症名医。
联系我们:
新浪微博:@良医汇罕见病新进展
微信公号:罕见病新进展
邮件:[email protected]
免责声明:
罕见病新进展是根据公开平台数据所集成的相关病程指南。本指南并非专业的医疗诊断意见。在您使用罕见病新进展app过程中如需获取专业的医疗诊断意见,请前往正规医疗机构咨询专业医生。
Hide Show More...

Screenshots

罕见病新进展 FAQ

  • Is 罕见病新进展 free?

    Yes, 罕见病新进展 is completely free and it doesn't have any in-app purchases or subscriptions.

  • Is 罕见病新进展 legit?

    Not enough reviews to make a reliable assessment. The app needs more user feedback.

    Thanks for the vote

  • How much does 罕见病新进展 cost?

    罕见病新进展 is free.

  • What is 罕见病新进展 revenue?

    To get estimated revenue of 罕见病新进展 app and other AppStore insights you can sign up to AppTail Mobile Analytics Platform.

User Rating
App is not rated in Australia yet.
Ratings History

罕见病新进展 Reviews

赞赞赞

小雪、球 on

China

罕见病的应用实在太少了,支持

各类罕见病知识

木声离 on

China

非常多罕见病基本信息,诊断和治疗方式,推荐学习

小众也值得一份关注

Lina_0421 on

China

谢谢你们的内容

yyl Yang on

China

一款对医疗非常有帮助的平台

500多种罕见病的知识!

sirwj on

China

500多种疾病,200多种药物,太有价值了!专业医生,患者必看!感谢!!!!

Store Rankings

Ranking History
App Ranking History not available yet
Category Rankings
App is not ranked yet

罕见病新进展 Competitors

Name
肿瘤前沿
小刘医生
肿瘤化疗助手患者端
中抗头条
携手抗痫,健康中国
肿瘤精准治疗MDT
N/A
血液专家
罕易
儿童罕见病平台
儿童罕见病就诊地图
罕佑
血液管理

罕见病新进展 Installs

Last 30 days

罕见病新进展 Revenue

Last 30 days

罕见病新进展 Revenue and Downloads

Gain valuable insights into 罕见病新进展 performance with our analytics.
Sign up now to access downloads, revenue, and more.
This page includes copyrighted content from third parties, shared solely for commentary and research in accordance with fair use under applicable copyright laws. All trademarks, including product, service, and company names or logos, remain the property of their respective owners. Their use here falls under nominative fair use as outlined by trademark laws and does not suggest any affiliation with or endorsement by the trademark holders.